Charles River Laboratories International Inc. logo

CRL

Charles River Laboratories International Inc.

$218.22

Earnings Summary

Revenue
$973.13Mn
Net Profits
$109.32Mn
Net Profit Margins
11.23%
PE Ratio
26.62

Highlights

Revenue:

Charles River Laboratories International Inc.’s revenue jumped 6.4% since last year same period to $973.13Mn in the Q2 2022. On a quarterly growth basis, Charles River Laboratories International Inc. has generated 6.48% jump in its revenue since last 3-months.

Net Profits:

Charles River Laboratories International Inc.’s net profit jumped 23.6% since last year same period to $109.32Mn in the Q2 2022. On a quarterly growth basis, Charles River Laboratories International Inc. has generated 17.52% jump in its net profits since last 3-months.

Net Profit Margins:

Charles River Laboratories International Inc.’s net profit margin jumped 16.17% since last year same period to 11.23% in the Q2 2022. On a quarterly growth basis, Charles River Laboratories International Inc. has generated 10.37% jump in its net profit margins since last 3-months.

PE Ratio:

Charles River Laboratories International Inc.’s price-to-earnings ratio after this Q2 2022 earnings stands at 26.62.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Charles River Laboratories International Inc. post its latest quarter earnings

EPS Estimate Current Quarter
2.74
EPS Estimate Current Year
2.74

Highlights

EPS Estimate Current Quarter:

Charles River Laboratories International Inc.’s earning per share (EPS) estimates for the current quarter stand at 2.74 - a 0.74% jump from last quarter’s estimates.

EPS Estimate Current Year:

Charles River Laboratories International Inc.’s earning per share (EPS) estimates for the current year stand at 2.74.

Key Ratios

Key ratios of the Charles River Laboratories International Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
2.77
Return on Assets (ROA)
0.06
Return on Equity (ROE)
0.18
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Charles River Laboratories International Inc.’s earning per share (EPS) jumped 6.13% since last year same period to 2.77 in the Q2 2022. This indicates that the Charles River Laboratories International Inc. has generated 6.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Charles River Laboratories International Inc.’s return on assets (ROA) stands at 0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Charles River Laboratories International Inc.’s return on equity (ROE) stands at 0.18.

Dividend Per Share (DPS):

Charles River Laboratories International Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-01
2.74
2.77
1.09%
2022-03-01
2.72
2.75
1.1%

Company Information

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

Organisation
Charles River Laboratories International Inc.
Headquarters
251 Ballardvale Street, Wilmington, MA, United States, 01887
Employees
18400
Industry
Commercial Services
CEO
James Foster